Abstract
Introduction: This systematic review aimed to assess the clinical evidence supporting the combination of syndrome differentiation (SD)-based herbal medicine (HM) and Western medicine (WM) in treating Parkinson’s disease (PD)-mild cognitive impairment (PD-MCI) and -dementia (PDD). Methods: Ten electronic bibliographic databases were searched from inception to March 4, 2024, for randomized controlled trials (RCTs) comparing SD-based HM plus conventional therapies with conventional therapies alone for PD-MCI and PDD. Two authors independently screened and selected studies and extracted data related to trial quality, characteristics, and results. The mean difference (MD) was used to analyze continuous variables, and meta-analysis was performed using Reviewer Manager 5.4 software. The risk of bias was assessed using the Cochrane Risk of Bias Tool. Results: For the 15 articles selected for review, 12 trials were included in the meta-analysis: 9 comprising 688 patients with PD-MCI and 3 comprising 264 patients with PDD and with a type of SD, such as “blood stasis and stirring wind” or “deficiency of the liver-kidney.” The meta-analysis showed significant differences favoring HM plus WM with respect to the Montreal Cognitive Assessment score for PD-MCI (MD = 2.30, 95% confidence interval [CI; 1.40, 3.19]; p < 0.00001, I2 = 76%) and PDD (MD = 3.14, 95% CI [0.48, 5.81]; p = 0.02, I2 = 82%) compared with WM alone. Improvement of cognitive impairment treated using “deficiency of the liver-kidney” SD-based HM plus WM in PD-MCI was more beneficial than that treated using WM alone. Conclusions: SD-based HM may serve as an adjunctive treatment for PD-MCI and PDD, improving cognitive function and alleviating PD symptoms. No severe adverse event was observed in the HM plus WM group, suggesting that HM may be safe for patients with cognitive impairment in PD. However, evidence regarding the efficacy of HM based on SD for PD-MCI and PDD is of poor quality, and all studies were conducted in China. Thus, and rigorous, multicenter, and international RCTs are required.
Journal Section:
Systematic Review / Systematische Übersichtsarbeit
References
1.
Poewe
W
, Seppi
K
, Tanner
CM
, Halliday
GM
, Brundin
P
, Volkmann
J
, et al. Parkinson disease
. Nat Rev Dis Primers
. 2017
;3
(1
):17013
. 2.
Caballol
N
, Martí
MJ
, Tolosa
E
. Cognitive dysfunction and dementia in Parkinson disease
. Mov Disord
. 2007
;22
(Suppl 17
):S358
–66
. 3.
Armstrong
MJ
, Okun
MS
. Diagnosis and treatment of Parkinson disease: a review
. JAMA
. 2020
;323
(6
):548
–60
. 4.
Aarsland
D
, Creese
B
, Politis
M
, Chaudhuri
KR
, Ffytche
DH
, Weintraub
D
, et al. Cognitive decline in Parkinson disease
. Nat Rev Neurol
. 2017
;13
(4
):217
–31
. 5.
Svenningsson
P
, Westman
E
, Ballard
C
, Aarsland
D
. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
. Lancet Neurol
. 2012
;11
(8
):697
–707
. 6.
Baiano
C
, Barone
P
, Trojano
L
, Santangelo
G
. Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: a meta-analysis
. Mov Disord
. 2020
;35
(1
):45
–54
. 7.
Belleville
S
, Fouquet
C
, Hudon
C
, Zomahoun
HTV
, Croteau
J
; Consortium for the Early Identification of Alzheimer’s disease-Quebec
. Neuropsychological measures that predict progression from mild cognitive impairment to alzheimer's type dementia in older adults: a systematic review and meta-analysis
. Neuropsychol Rev
. 2017
;27
(4
):328
–53
. 8.
Aarsland
D
, Bronnick
K
, Williams-Gray
C
, Weintraub
D
, Marder
K
, Kulisevsky
J
, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis
. Neurology
. 2010
;75
(12
):1062
–9
. 9.
Seppi
K
, Ray Chaudhuri
K
, Coelho
M
, Fox
SH
, Katzenschlager
R
, Perez Lloret
S
, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review
. Mov Disord
. 2019
;34
(2
):180
–98
. 10.
Nikolin
S
, Huggins
C
, Martin
D
, Alonzo
A
, Loo
CK
. Safety of repeated sessions of transcranial direct current stimulation: a systematic review
. Brain stimul
. 2018
;11
(2
):278
–88
. 11.
Cerasa
A
, Gioia
MC
, Salsone
M
, Donzuso
G
, Chiriaco
C
, Realmuto
S
, et al. Neurofunctional correlates of attention rehabilitation in Parkinson’s disease: an explorative study
. Neurol Sci
. 2014
;35
(8
):1173
–80
. 12.
Chung
V
, Liu
L
, Bian
Z
, Zhao
Z
, Leuk Fong
W
, Kum
WF
, et al. Efficacy and safety of herbal medicines for idiopathic Parkinson’s disease: a systematic review
. Mov Disord
. 2006
;21
(10
):1709
–15
. 13.
Shan
C-S
, Zhang
H-F
, Xu
Q-Q
, Shi
Y-H
, Wang
Y
, Li
Y
, et al. Herbal medicine formulas for Parkinson’s disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled clinical trials
. Front Aging Neurosci
. 2018
;10
:349
. 14.
Jiang
M
, Lu
C
, Zhang
C
, Yang
J
, Tan
Y
, Lu
A
, et al. Syndrome differentiation in modern research of traditional Chinese medicine
. J Ethnopharmacol
. 2012
;140
(3
):634
–42
. 15.
Goldman
JG
, Litvan
I
. Mild cognitive impairment in Parkinson's disease
. Minerva Med
. 2011
;102
(6
):441
–59
.16.
Siciliano
M
, De Micco
R
, Russo
AG
, Esposito
F
, Sant'Elia
V
, Ricciardi
L
, et al. Memory phenotypes in early, de novo Parkinson’s disease patients with mild cognitive impairment
. Mov Disord
. 2023
;38
(8
):1461
–72
. 17.
Dong
L
, Hyde
AJ
, Zhang
AL
, Xue
CC
, May
BH
. Chinese herbal medicine for mild cognitive impairment using montreal cognitive assessment: a systematic review
. J Altern Complement Med
. 2019
;25
(6
):578
–92
. 18.
Kim
TH
, Cho
KH
, Jung
WS
, Lee
MS
. Herbal medicines for Parkinson's disease: a systematic review of randomized controlled trials
. PLoS One
. 2012
;7
(5
):e35695
. 19.
Zhang
Y
, Wang
Z-Z
, Sun
H-M
, Li
P
, Li
Y-F
, Chen
N-H
. Systematic review of traditional Chinese medicine for depression in Parkinson’s disease
. Am J Chin Med
. 2014
;42
(5
):1035
–51
. 20.
Jun
P
, Zhao
H
, Jung
IC
, Kwon
O
, Han
C-H
, Won
J
, et al. Efficacy of herbal medicine treatment based on syndrome differentiation for Parkinson’s disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials
. Front Pharmacol
. 2023
;14
:1108407
. 21.
Jun
P
, Zhao
H
, Kwon
O
, Jang
JH
. Efficacy of traditional herbal medicine treatment based on pattern identification for idiopathic Parkinson’s disease: a protocol for systematic review and meta-analysis
. Evid Based Complement Alternat Med
. 2022
;2022
:4777849
. 22.
Litvan
I
, Goldman
JG
, Tröster
AI
, Schmand
BA
, Weintraub
D
, Petersen
RC
, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines
. Mov Disord
. 2012
;27
(3
):349
–56
. 23.
Yang
L
, Yuan
X
, Wang
L
, Li
C
, Li
H
, Li
X
. Clinical efficacy of memantine hydrochloride combined with Yizhi Xingnao decoction in the treatment of Parkinson’s dementia
. Chinese Journal of intergrative Medicine on Cardio-Cerebrovascular disease
. 2022
;20
(08
):1516
–9
.24.
Yang
L
, Yarui
M
, Li
Z
, Han
G
, Zhang
J
. Clinical study on Pingchan Yizhi decoction combined with routine therapy for Parkinson’s disease dementia of liver-kidney deficiency type
. New Chin Med
. 2023
;55
(18
):32
–5
.25.
Nasreddine
ZS
, Phillips
NA
, Bédirian
V
, Charbonneau
S
, Whitehead
V
, Collin
I
, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
. J Am Geriatr Soc
. 2005
;53
(4
):695
–9
. 26.
Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease
. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations
. Mov Disord
. 2003
;18
(7
):738
–50
. 27.
Tombaugh
TN
, McIntyre
NJ
. The mini-mental state examination: a comprehensive review
. J Am Geriatr Soc
. 1992
;40
(9
):922
–35
. 28.
McCully
KS
. Homocysteine metabolism, atherosclerosis, and diseases of aging
. Compr Physiol
. 2015
;6
(1
):471
–505
. 29.
O'Suilleabhain
PE
, Sung
V
, Hernandez
C
, Lacritz
L
, Dewey
RB
Jr, Bottiglieri
T
, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations
. Arch Neurol
. 2004
;61
(6
):865
–8
. 30.
Shi
X
, Zheng
J
, Ma
J
, Wang
Z
, Sun
W
, Li
M
, et al. Low serum uric acid levels are associated with the nonmotor symptoms and brain gray matter volume in Parkinson’s disease
. Neurol Sci
. 2022
;43
(3
):1747
–54
. 31.
Chang
K-H
, Chen
C-M
. The role of oxidative stress in Parkinson’s disease
. Antioxidants
. 2020
;9
(7
):597
. 32.
33.
Dalton
JE
, Bolen
SD
, Mascha
EJ
. Publication bias: the elephant in the review
. Anesth Analg
. 2016
;123
(4
):812
–3
. 34.
Guyatt
GH
, Oxman
AD
, Vist
GE
, Kunz
R
, Falck-Ytter
Y
, Alonso-Coello
P
, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
. BMJ
. 2008
;336
(7650
):924
–6
. 35.
Zhao
L
. Research of Treatment of mild cognitive impairment in Parkinson’s disease by tonifying kidney and detoxicating method
. Capital Medical University
; 2017
.36.
Xu
Q
, Zhu
B
, Ji
J
, Lin
C
, Chen
S
. Clinical study on Jianpi Huatan prescription combined with cognitive training for mild cognitive impairment in Parkinson’s disease
. New Chin Med
. 2023
;55
(17
):91
–5
.37.
Feng
C
. Clinical observation of Tian Ma Xing Nao Capsule in treating mild cognitive impairment of Parkinson's Disease (insufficiency of myelin sea)
. Yunnan University of traditional Chinese medicine
; 2023
.38.
Li
Q
. The correlative of traditional Chinese Medicine syndromes with cognitive feature in PD and the clinical study of KangZhen ZhiJing capsule treat PD-MCI with blood stasis and wind ACT
. Anhui University of traditional Chinese medicine
; 2016
.39.
Wang
F
. Clinical study of KangZhen ZhiJing capsule treat on cogvative behaviors and neuroimaging in patients with Parkinson’s disease of blood stasis and with act
. Anhui University of Traditional Chinese Medicine
; 2018
.40.
Peng
Z
, Xie
A
, Guo
J
, Liu
W
, Kuang
J
, He
X
, et al. Effect of Huoxue Dingzhan decoction combined with Doxyhydrazide on cognitive function and oxidative stress biomarker level in patients with Parkinson's disease and cognitive impairment
. Arch Trad Chin Med
. 2021
;39
(2
).41.
Wen
M
. Clinical efficacy of Phlegm-transforming and anti-quivering formula in the treatment of PD-MCI patients with Phlegm blockage
. Guangxi University of traditional Chinese medicine
; 2022
.42.
Yang
X
. Clinical study of Buyigan Shen Fang in the treatment of parkinson’s disease with mild cognitive dysfunction due to Liver and Kidney insufficiency Guangzhou University of traditional Chinese medicine
; 2019
.43.
San
Y
, Zhang
B
, Wei
L
, Hu
Y
, Zhu
D
. Clinical observation on cognitive function of Parkinson’s disease treated by integrated traditional Chinese and Western medicine
. J TCM
. 2019
;41
(6
):29
–31
.44.
Shen
L
, Qiao
X
, Wang
P
, Gu
J
, Chen
X
, Shen
L
, et al. Clinical observation on Ziyin Qutan Kaiqiao Decoction in the treatment of Parkinson’s disease with mild cognitive impairment (syndrome of yin deficiency of liver and kidney)
. Acta Univ Trad Med Sinensis Pharmacologiaeque Shanghai
. 2020
;34
(4
):11
–4
.45.
Zheng
J
, Li
W
, Jia
Z
, Wang
S
, Su
F
, Dou
R
, et al. Efficacy evaluation of Zuogui pills combined with butylphthalide in the adjuvant treatment of mild cognitive impairment in Parkinson’s disease
. China Pharm
. 2024
;33
(4
):111
–4
.46.
Cheng
Y
. Clinical study on the treatment of BuGanYiShen tiansui decoction for Parkinson’s disease dementia with yin deficiency of liver and kidney
. Anhui University of Traditional Chinese Medicine
; 2020
.47.
Zhang
Z
, Jin
X
, Yang
L
, Shen
Y
, Junbiao
T
, Su
Z
, et al. Effect of Huanglian Jiedu decoction combined with Dopasazid tablets on cognitive impairment of Parkinson's disease and its effect on sleep quality and depressive mood
. J Liaoning Univ Trad Chin Med
. 2023
:1
–13
.48.
Jokinen
P
, Brück
A
, Aalto
S
, Forsback
S
, Parkkola
R
, Rinne
JO
. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy
. Parkinsonism Relat Disord
. 2009
;15
(2
):88
–93
. 49.
He
Z-Q
, Huan
P-F
, Wang
L
, He
J-C
. Paeoniflorin ameliorates cognitive impairment in Parkinson’s disease via JNK/p53 signaling
. Metab Brain Dis
. 2022
;37
(4
):1057
–70
. 50.
Fan
X
, Zhang
L
, Li
H
, Chen
G
, Qi
G
, Ma
X
, et al. Role of homocysteine in the development and progression of Parkinson’s disease
. Ann Clin Transl Neurol
. 2020
;7
(11
):2332
–8
. 51.
Lamberti
P
, Zoccolella
S
, Armenise
E
, Lamberti
S
, Fraddosio
A
, De Mari
M
, et al. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration
. Eur J Neurol
. 2005
;12
(5
):365
–8
. 52.
Du
W
, Liang
X
, Wang
S
, Lee
P
, Zhang
Y
. The underlying mechanism of paeonia lactiflora pall. in Parkinson’s disease based on a network pharmacology approach
. Front Pharmacol
. 2020
;11
:581984
. 53.
Zhan
H-D
, Zhou
H-Y
, Sui
Y-P
, Du
X-L
, WangDai
W-L
, Sui
F
, et al. The rhizome of Gastrodia elata Blume–An ethnopharmacological review
. J Ethnopharmacol
. 2016
;189
:361
–85
. 54.
Chik
SC
, Or
TCT
, Luo
D
, Yang
CLH
, Lau
ASY
. Pharmacological effects of active compounds on neurodegenerative disease with gastrodia and uncaria decoction, a commonly used poststroke decoction
. Sci World J
. 2013
;2013
:896873
. 55.
Gao
Y
, Wei
Y
, Wang
Y
, Gao
F
, Chen
Z
. Lycium barbarum: a traditional Chinese herb and a promising anti-aging agent
. Aging Dis
. 2017
;8
(6
):778
–91
. 56.
Chung
S-Y
, Kang
M
, Hong
S-B
, Bae
H
, Cho
S-H
. Standardized Lycium chinense fruit extract enhances attention and cognitive function in healthy young people by a double-blind, randomized, placebo-controlled, crossover trial
. J Res Med Sci
. 2019
;24
(1
):102
. 57.
Wang
X
, Pang
L
, Zhang
Y
, Xu
J
, Ding
D
, Yang
T
, et al. Lycium barbarum polysaccharide promotes nigrostriatal dopamine function by modulating PTEN/AKT/mTOR pathway in a methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) murine model of Parkinson’s disease
. Neurochem Res
. 2018
;43
(4
):938
–47
. 58.
Hongzhi
C
, Jiancheng
H
, Long
T
, Canxing
Y
, Zhe
Z
. Traditional Chinese Medicine symptom pattern analysis for Parkinson’s disease
. J Tradit Chin Med
. 2017
;37
(5
):688
–94
. 59.
Hu
Y
, Gu
S
, Yuan
X
, Li
H
, Yuan
C
, Ye
Q
. Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson’s disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial
. Chin Med
. 2022
;17
(1
):68
. 60.
Parkinson Study Group STEADY-PD III Investigators
. Isradipine versus placebo in early Parkinson disease: a randomized trial
. Ann Intern Med
. 2020
;172
(9
):591
–8
. 61.
Liang
Y-T
, Lin
C-Y
, Wang
Y-H
, Chou
H-H
, Wei
JC-C
. Associations of Chinese herbal medicine usage with risk of dementia in patients with Parkinson’s disease: a population-based, nested case–control study
. J Altern Complement Med
. 2021
;27
(7
):606
–12
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
